Real‐World Study of EGFR‐TKI Rechallenge With Another TKI After First‐Line Osimertinib Discontinuati...
Real‐World Study of EGFR‐TKI Rechallenge With Another TKI After First‐Line Osimertinib Discontinuation in Patients With EGFR‐Mutated Non‐Small Cell Lung Cancer: A Subset Analysis of the Reiwa Study
About this item
Full title
Author / Creator
Publisher
Melbourne: John Wiley & Sons Australia, Ltd
Journal title
Language
English
Formats
Publication information
Publisher
Melbourne: John Wiley & Sons Australia, Ltd
Subjects
More information
Scope and Contents
Contents
ABSTRACT
Introduction
First‐line osimertinib is widely used to treat patients with epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung cancers (NSCLC). In clinical practice, rechallenge therapy with another EGFR‐tyrosine kinase inhibitor (TKI) is often performed after first‐line TKI discontinuation owing to resistance or toxic...
Alternative Titles
Full title
Real‐World Study of EGFR‐TKI Rechallenge With Another TKI After First‐Line Osimertinib Discontinuation in Patients With EGFR‐Mutated Non‐Small Cell Lung Cancer: A Subset Analysis of the Reiwa Study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_b1f6c4f29e5245aaa2131f26bdc0b4fd
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_b1f6c4f29e5245aaa2131f26bdc0b4fd
Other Identifiers
ISSN
1759-7706,1759-7714
E-ISSN
1759-7714
DOI
10.1111/1759-7714.15507
